

CITATION REPORT

List of articles citing

Repeated Administration of the Converting Enzyme Inhibitor Cilazapril to Normal Volunteers

DOI: 10.1097/00005344-198701000-00007

Journal of Cardiovascular Pharmacology, 1987, 9, 39-44.

Source: <https://exaly.com/paper-pdf/19011141/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
140	Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers. 1987 , 41, 639-44		26
139	The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. 1988 , 44, 173-8		20
138	Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. 1988 , 15, 295-318		49
137	Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. 1988 , 26, 547-56		17
136	Individual responses to converting enzyme inhibitors and calcium antagonists. <i>Hypertension</i> , 1988 , 11, 166-73	8.5	72
135	Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers. <i>Hypertension</i> , 1989 , 13, 948-53	8.5	43
134	Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. <i>Hypertension</i> , 1989 , 13, 941-7	8.5	52
133	Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers. 1989 , 36, 587-91		2
132	Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin I. 1989 , 10, 489-92		16
131	Clinical pharmacology of cilazapril. 1989 , 87, 45S-49S		11
130	Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man. 1989 , 27 Suppl 2, 189S-197S		8
129	A pharmacokinetic study of cilazapril in elderly and young volunteers. 1989 , 27 Suppl 2, 211S-215S		16
128	A pharmacokinetic study of cilazapril in patients with congestive heart failure. 1989 , 27 Suppl 2, 267S-273S		9
127	Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function. 1989 , 27 Suppl 2, 283S-287S		7
126	Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients. 1989 , 27 Suppl 2, 309S-315S		2
125	Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. 1989 , 27 Suppl 2, 317S-322S		6
124	Pharmacokinetics of angiotensin converting enzyme inhibitors. 1989 , 28 Suppl 2, 133S-139S; discussion 140S		8

123	Cilazapril. 1990 , 8, 1-24		14
122	Pharmacokinetics of cilazapril during repeated oral dosing in healthy young volunteers. 1990 , 15, 63-7		4
121	Cyclosporin reduces renal blood flow through vasoconstriction of arcuate arteries in the hydronephrotic rat model. 1990 , 68, 166-74		12
120	Newer ACE inhibitors. A look at the future. 1990 , 40, 800-28		63
119	Pharmacokinetics of perindopril and its metabolites in healthy volunteers. 1990 , 4, 175-89		28
118	Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II. 1990 , 39, 513-8		23
117	Clinical pharmacology of cilazapril. 1991 , 41 Suppl 1, 3-10		6
116	Cilazapril. A review. 1991 , 41 Suppl 1, 18-24		28
115	Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. 1991 , 41, 799-820		23
114	Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact. <i>American Journal of Hypertension</i> , 1991 , 4, 602-9	2.3	34
113	Renin inhibitors. 1991 , 22, 207-50		17
112	Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. 1991 , 50, 181-91		18
111	Ro 42-5892 is a potent orally active renin inhibitor in primates. <i>Hypertension</i> , 1991 , 18, 22-31	8.5	120
110	Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. 1991 , 83, 552-8		40
109	Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. 1991 , 83, 1333-42		241
108	Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. 1992 , 85, 1-8		206
107	Mechanisms involved in cardiac enlargement and congestive heart failure development after acute myocardial infarction. 1992 , 81, 213-20		10
106	Cilazapril: an overview of its efficacy and safety in hypertension. 1992 , 80, 34-41		2

105	Protection from hypoxemia-induced renal dysfunction by the thiophosphate WR-2721. 1992 , 41, 80-7		5
104	Visualization of serotonin effects on renal vessels of rats. 1993 , 43, 314-23		21
103	Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. 1993 , 54, 567-77		19
102	Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. 1993 , 36, 547-54		15
101	Disparity between blood pressure and PRA inhibition after administration of a renin inhibitor to anesthetized dogs: methodological considerations. 1993 , 15, 663-81		6
100	Comparative effects of three different potent renin inhibitors in primates. <i>Hypertension</i> , 1993 , 22, 9-17	8.5	25
99	Hygroma renale: pararenal lymphatic cysts associated with renin-dependent hypertension (Page kidney). Case report on bilateral cysts and successful therapy by marsupialization. 1993 , 150, 953-7		51
98	Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. <i>Hypertension</i> , 1993 , 22, 339-47	8.5	181
97	Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. <i>American Journal of Hypertension</i> , 1993 , 6, 349-56	2.3	33
96	The Hydronephrotic Kidney: A Model to Study Renal Microcirculation. 1993 , 169-183		1
95	Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. <i>Hypertension</i> , 1994 , 24, 163-9	8.5	19
94	Renal sodium handling in patients with untreated hypertension and white coat hypertension. <i>Hypertension</i> , 1994 , 23, 496-502	8.5	40
93	Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. 1994 , 90, 2748-56		30
92	R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. <i>American Journal of Hypertension</i> , 1994 , 7, 295-301	2.3	8
91	Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. 1994 , 46, 537-43		14
90	Major role of the renin angiotensin system in the neointima formation after vascular injury in guinea pigs. 1994 , 54, PL87-92		5
89	Reciprocal changes in vasoactive hormones in the rat myocardial infarction model of heart failure. 1994 , 1, 63-9		
88	Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany. 1994 , 15 Suppl D, 113-22		31

87	Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. 1994 , 87, 567-74		118
86	A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. 1996 , 50, 57-62		9
85	Pharmacokinetics and haemodynamic effects of the angiotensin converting enzyme inhibitor cilazapril in hypertensive patients with normal and impaired renal function. 1996 , 42, 615-20		1
84	Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. <i>Journal of Hypertension</i> , 1997 , 15, 1809-12	1.9	29
83	Effects of amlodipine, a calcium channel blocker, on rat renal arterioles. 1997 , 58, 375-380		10
82	Prevention of hypoxemia-induced renal dysfunction by perindoprilat in the rabbit. 1997 , 61, 2157-65		10
81	DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. 1997 , 61, 59-69		7
80	Hormone responses to stress in patients with major burns. 1998 , 51, 388-92		26
79	Circadian variations of renal sodium handling in patients with orthostatic hypotension. 1998 , 54, 1276-82		19
78	Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. 1998 , 54, 2089-97		19
77	Effects of barnidipine hydrochloride, a calcium channel blocker, on renal microcirculation in rats: a pilot study. 1998 , 59, 826-834		9
76	Neural and hypotensive effects of angiotensin II receptor blockade. <i>Hypertension</i> , 1998 , 31, 378-83	8.5	28
75	Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. <i>Hypertension</i> , 1998 , 31, 1324-30	8.5	178
74	Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. <i>Journal of Hypertension</i> , 1998 , 16, 385-93	1.9	52
73	Prolonged exercise increases peripheral plasma ACTH, CRH, and AVP in male athletes. <i>Journal of Applied Physiology</i> , 1998 , 85, 835-41	3.7	48
72	Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. 1999 , 66, 76-84		226
71	Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. 1999 , 82, 35-43		14
70	Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. <i>Journal of Hypertension</i> , 1999 , 17, 427-37 ¹⁹		24

69	Effect of lacidipine on blood pressure, vasoactive hormones, and haemorheology in elderly patients with essential hypertension. <i>Journal of Human Hypertension</i> , 2000 , 14, 473-5	2.6	1
68	Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. 2000 , 55, 749-54		12
67	Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. 2000 , 85, 1016-20		69
66	Compensatory up-regulation of angiotensin II subtype 1 receptors in alpha ENaC knockout heterozygous mice. 2001 , 59, 2216-21		15
65	Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. <i>Hypertension</i> , 2002 , 39, E1-8	8.5	322
64	Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. 2002 , 13, 1509-16		63
63	Cardiovascular activity1. 2002 , 26-276		
62	Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002 , 71, 68-76		75
61	Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. 2003 , 92, 406-10		97
60	Estimation of lot-to-lot relative potency in the preparation of radioimmunoassay calibrators. 2003 , 24, 243-63		1
59	Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. <i>Hypertension</i> , 2003 , 42, 1137-43	8.5	286
58	Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. 2004 , 89, 1140-5		95
57	Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE ^{-/-} mice. <i>Hypertension</i> , 2004 , 44, 277-82	8.5	114
56	Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress. 2004 , 65, 238-44		7
55	Renal endothelin receptor type B upregulation in rats with low or high renin hypertension. <i>Journal of Hypertension</i> , 2004 , 22, 1797-803	1.9	
54	Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men. 2005 , 68, 688-94		6
53	Plasma renin and aldosterone measurements in low renin hypertensive states. 2005 , 16, 86-91		75
52	Severe hyperlipidemia causes impaired renin-angiotensin system function in apolipoprotein E deficient mice. 2006 , 186, 86-91		10

51	The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. 2006 , 291, E1228-34		14
50	Plasma aldosterone is independently associated with the metabolic syndrome. <i>Hypertension</i> , 2006 , 48, 239-45	8.5	172
49	Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. <i>Hypertension</i> , 2007 , 49, 276-84	8.5	152
48	CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. <i>Hypertension</i> , 2007 , 49, 1007-14	8.5	53
47	Cardiovascular Activity. 2007 , 47-391		
46	Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. 2007 , 61, 1461-8		70
45	A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. 2008 , 22, 469-78		9
44	Clinical pharmacokinetics and pharmacodynamics of aliskiren. 2008 , 47, 515-31		120
43	Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. 2008 , 117, 2262-9		87
42	Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. 2008 , 117, 3199-205		141
41	Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. <i>Hypertension</i> , 2008 , 51, 1306-11	8.5	108
40	Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. <i>Clinical Chemistry</i> , 2009 , 55, 867-77	5.5	145
39	Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. <i>American Journal of Hypertension</i> , 2009 , 22, 112-21	2.3	52
38	Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren. <i>Journal of the American Society of Hypertension</i> , 2009 , 3, 315-20		10
37	Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. <i>Diabetologia</i> , 2010 , 53, 1568-75	10.3	26
36	A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. <i>Journal of Hypertension</i> , 2010 , 28, 1307-12	1.9	32
35	Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 1358-66	2.9	14
34	Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. <i>Hypertension</i> , 2010 , 55, 54-60	8.5	22

33	Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2225-31	4.3	42
32	Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2441-8	4	12
31	Initial and steady state pharmacokinetics of cilazapril in congestive cardiac failure. <i>Journal of Pharmacy and Pharmacology</i> , 1991 , 43, 406-10	4.8	2
30	The renin prosequence enhances constitutive secretion of renin and optimizes renin activity. <i>Current Neurovascular Research</i> , 2011 , 8, 121-30	1.8	1
29	Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1351-8	4	12
28	Plasma renin activity enzyme-kinetic assay: protection of Angiotensin I from bacterial degradation. <i>Clinical Chemistry</i> , 2011 , 57, 529-30; author reply 530-1	5.5	5
27	Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. <i>Journal of Human Hypertension</i> , 2011 , 25, 186-95	2.6	25
26	The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. <i>American Journal of Hypertension</i> , 2011 , 24, 1164-80	2.3	97
25	Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC-MS/MS. <i>Bioanalysis</i> , 2012 , 4, 2843-50	2.1	19
24	Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. <i>Journal of Hypertension</i> , 2012 , 30, 561-6	1.9	17
23	Renin-Dependent Hypertension in Mice Requires the NLRP3- Inflammasome. <i>Journal of Hypertension: Open Access</i> , 2013 , 03,		1
22	Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone. <i>Journal of Veterinary Internal Medicine</i> , 2014 , 28, 1471-8	3.1	15
21	Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism. <i>Journal of Hypertension</i> , 2015 , 33, 1014-22	1.9	7
20	The Aldosterone/Renin Ratio as a Diagnostic Tool for the Diagnosis of Primary Hypoaldosteronism in Newborns and Infants. <i>Hormone Research in Paediatrics</i> , 2015 , 84, 43-8	3.3	1
19	Potent inhibition of human organic cation transporter 2 (hOCT2) by Ecbaroline alkaloids. <i>Xenobiotica</i> , 2017 , 47, 1112-1120	2	4
18	Dietary Sodium Modifies Serum Uric Acid Concentrations in Humans. <i>American Journal of Hypertension</i> , 2017 , 30, 1196-1202	2.3	8
17	New Insights into Cardiac and Vascular Natriuretic Peptides: Findings from Young Adults Born with Very Low Birth Weight. <i>Clinical Chemistry</i> , 2018 , 64, 363-373	5.5	9
16	No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent. <i>Journal of Applied Physiology</i> , 2021 , 130, 226-236	3.7	3

15	Regulation of plasma volume in male lowlanders during 4 days of exposure to hypobaric hypoxia equivalent to 3500m altitude. <i>Journal of Physiology</i> , 2021 , 599, 1083-1096	3.9	9
14	Dietary sodium intake does not alter renal potassium handling and blood pressure in healthy young males. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	0
13	Cardiovascular activity. 1997 , 1-149		1
12	Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 252-8	3.1	8
11	SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 29, 444-50	3.1	11
10	Cloning and characterization of marmoset renin: comparison with human renin. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 34, 893-7	3.1	3
9	The effect of glycerol and desmopressin on exercise performance and hydration in triathletes. <i>Medicine and Science in Sports and Exercise</i> , 1998 , 30, 1263-9	1.2	27
8	Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. <i>Hypertension</i> , 1995 , 25, 14-21	8.5	69
7	Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. <i>Hypertension</i> , 1995 , 25, 602-9	8.5	76
6	Chronic nitric oxide synthase inhibition and carotid artery distensibility in renal hypertensive rats. <i>Hypertension</i> , 1995 , 26, 332-6	8.5	7
5	Renin and angiotensin II receptor gene expression in kidneys of renal hypertensive rats. <i>Hypertension</i> , 1995 , 26, 733-7	8.5	21
4	Two-kidney, one clip and one-kidney, one clip hypertension in mice. <i>Hypertension</i> , 1997 , 29, 1025-30	8.5	111
3	Lactotriptides Inhibiting ACE1 Elevate the Plasma Bradykinin Concentration Acutely in a Placebo-Controlled, Double-Blind, Cross-Over, 4-Week Trial in Healthy Volunteers. <i>Pharmacology & Pharmacy</i> , 2018 , 09, 229-241	0.3	2
2	Cardiovascular Analysis In Vivo. 2014 , 1-105		
1	Cardiovascular Analysis In Vivo. 2016 , 41-133		